Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02556632 · ClinicalTrials.gov registry record · Phase 2
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
A Phase 2 study, sponsored by Gary Morrow.
- Completed
- Registry status
- Phase 2
- Development phase
- 191
- Enrollment target
NCT02556632 is a Phase 2 study that has completed, run by Gary Morrow. The registered enrollment target is 191 participants.
The verdict
NCT02556632, a Phase 2 study, has completed, sponsored by Gary Morrow.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 191 participants
- Enrollment target
Study Summary
This randomized pilot phase II trial studies and compares prophylactic topical agents in reducing radiation-induced dermatitis in patients with non-inflammatory breast cancer or breast cancer in situ. The prophylactic topical agents, such as curcumin-based gel or HPR Plus, may reduce the severity of the radiation-induced dermatitis by minimizing water loss and inflammation during radiation therapy.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DRUG Curcumin-based Gel
- PROCEDURE Dermatologic Complications Management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2015-10-13 |
| Est. Completion | 2016-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02556632
The ClinicalTrials.gov registry entry for NCT02556632 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gary Morrow, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02556632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02556632 about?
NCT02556632 is a clinical study titled "Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer". This randomized pilot phase II trial studies and compares prophylactic topical agents in reducing radiation-induced dermatitis in patients with non-inflammatory breast cancer or breast cancer in situ. The prophylactic topical agents, such as curcumin-based gel or HPR Plus, may reduce the severity of...
What is the current status of trial NCT02556632?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 191 participants. The study started on 2015-10-13. Estimated completion is 2016-09-30.
What interventions are being tested in trial NCT02556632?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Curcumin-based Gel (DRUG), Dermatologic Complications Management (PROCEDURE).
Who is sponsoring clinical trial NCT02556632?
This trial is sponsored by Gary Morrow, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.